Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Clinical trial NCT06547944 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06547944
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-01
- Primary completion
- 2025-12-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.